期刊文献+

P53,C-erbB2,rasP21,nm23-H1基因表达与大肠癌淋巴结转移的关系 被引量:1

P53,C-erbB2,rasP21,nm23-H1's expression and lymphatic metastasis in human colorectal carcinoma
下载PDF
导出
摘要 目的探讨大肠癌组织中癌基因和抑癌基因在大肠癌淋巴转移中的作用。方法利用免疫组化方法(SP法)检测大肠癌组织中癌基因和抑癌基因。结果224例大肠癌患者中,淋巴结的转移率随分化程度降低而增高;随癌组织浸润深度增加,淋巴结的转移率明显提高;淋巴结转移的阳性率还随癌基因及其产物P53、C-erbB2、rasP21的出现而增加,而随nm23-H1的表达而降低。结论癌基因、抑癌基因的检测将有助于研究肿瘤淋巴转移的原因和机制,并对淋巴转移进行预测。 Objective To investigate the effect of P53, rasP21, nm23 H1 genes on lymphatic metasasis in human colorectal carcinoma.Methods The expression of P53, rasP21,C-erbB2 and nm23 H1 in human colorectal carcinoma were studied immunohistochemically (S-P). Results Of 224 cases of colorectal carcinoma the lymphatic metastasis were significantly higher in the primary colorectal carcinomas with tissue infiltration to subserosa ( P 〈 0.01).The lymphatic metastasis were significantly higher in P53, C-erbB2, rasP21 positive expression ( P 〈 0.05) and negative expression of nm23-H1 ( P 〈0.05).Conclusion The expression of P53,C-erbB2, rasP21 and nm23- H1 were associated lymphatic metastasis in human colorectal carcinoma. These findings suggest a potential role of P53, C - erbB2, rasP21 and nm23-H1 in lymphatic metastasis in human colorectal carcinoma angiogenesis.
出处 《河北医药》 CAS 2006年第12期1136-1137,共2页 Hebei Medical Journal
基金 河北省科技厅指导性科研项目(编号:20042761570)
关键词 大肠癌 P53 C-ERBB2 ras P21 NM23-H1 colorectal eareinoma P53 C-erbB2 rasP21 nm23-H1
  • 相关文献

参考文献8

  • 1Hsu CH,Chen CL,Hong RL,et al.Prognostic value of multidrug resistance 1,glutathione-S-transferase-pi and P53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.Oncology,2002,62:305-312.
  • 2郑少青.突变p53基因在恶性淋巴瘤中的表达[J].河北医药,2000,22(5):347-347. 被引量:2
  • 3李收,孙晋璞,王立甫.肿瘤标记物与p53在肿瘤表达中相关性的研究进展[J].中国全科医学,2006,9(11):934-936. 被引量:3
  • 4Michaelis M,Kotchetkov R,Vogei JU,et al.Cytomegalovirus infection blocks apoptosis in cancer cells.Cell Mol Life Sci,2004,61:1307-1330.
  • 5Bendardaf R,Lamlum H,Pyrhonen S.Prognostic and predictive molecular markers in colorectal carcinoma.Anticancer Res,2004,24:2519-2530.
  • 6Agnantis NJ,Goussia AC,Stefanou D,et al.An update approach for their prognostic significance,In Vivo,2003,17:609-618.
  • 7Ramakrishna G,Sithanandam G,Cheng RY,et al.K-ras p21 expression and activity in lung and lung tumors.Exp Lung Res,2000,26:659-671.
  • 8Tahara E.Genetic pahtways of two types of gastric cancer.IARC Sci Publ,2004,157:327-349.

二级参考文献33

  • 1许良中.癌基因与抗癌基因在肿瘤病理学上的应用[J].国外医学(肿瘤学分册),1993,20(4):200-203. 被引量:13
  • 2王申五,李延春,吴新艺,白桃,颜世庆.髓性白血病细胞p53基因表达下调[J].中华肿瘤杂志,1996,18(2):102-104. 被引量:5
  • 3LevineAJ MonandJ FinlayCA.The p53 tumur suppressor gene[J].Nature,1991,351(6326):453-456.
  • 4Davidoff AM,HumphreyPA,Iglehart JD,et al.Genetic basis for p53 overexpression in human breast cancer[J].J Proc Natl Acad Sci USA,1991,88(11):5006-5010.
  • 5Yoshimura R,Sano H,Masuda C,et al.Expression of cyclooxygenase-2 in prostate carcinoma[J].Cancer,2000,89(3):589-596.
  • 6Smith WL,Garavito RM,Dewitt DL,et al.Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2[J].J Biol chem,1996,271(52):33157-33160.
  • 7Lu CD,Altieri DC,Tanigawa N.Expression of a novel antiapoptosis gene,Survivin,correlated with tumor cell apoptosis and p53 accumulation in gastric carcinoma[J].Cancer Res,1998,58(9):1808-1812.
  • 8Weinstein RS,Kusyak JR,Kluskens LF,et al.P-glycoprotein in pathology:the multidrug resistance gene family in humans[J].Hum Pathol,1990,21(1):24-27.
  • 9Nguyen KT,Lin B,Ueda K,et al.Transactivation of the human multidrug resistance (MDR)gene promoter by p53 multants[J].Oncol Res,1994,6(2):71-74.
  • 10Hamaoka R,Yaginuma Y,Takahashi T,et al.Different expression patterns of nitric oxide systhase oxide systhase isozymes in various gynecological Cancers[J].Cancer Res Chin Oncol,1999,125(6):321-326.

共引文献3

同被引文献4

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部